Date: April. 29 th , 2022
Your Name: Lukas Käsmann
Manuscript Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudinal biomarker study
Manuscript number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XYes	Honoraria from AMGEN
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V. None	
6	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
	meetings and, or traver		
8	Patents planned, issued or	X None	
O	pending	XNone	
	F		
9	Darticipation on a Data	V None	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author receives consulting honoraria from AMGEN.

Please place an "X" next to the following statement to indicate your agreement:

Date: April. 29 th , 2022	
Your Name: Julian T	augner
Manuscript Title:	Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to characterize t	umor response and control in patients with unresectable stage III NSCLC treated with
concurrent chemoradioth	erapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudinal l	piomarker study
Manuscript number (if kn	own): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	
	nase summarize the above connone.		

Date:April 19 th , 2022
/our Name: Chukwuka Eze
Manuscript Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to
characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent
chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective
ongitudinal biomarker study
Vanuscript number (if known): TLCR-21-1010-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

2.2	Name of the state	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	German Cancer Aid	Funding for conducting other studies outside the submitted work.
3	Royalties or licenses	X None	

4	Consulting fees	Novartis	Outside the submitted work
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	Novartis	Outside the submitted work
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author receives consulting fees and travels support from Novartis outside the submitted work. CE reports receiving funding from the German Cancer aid outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

Date:	April. 29 th , 2022
Your Nam	e: Saskia Kenndoff
Manuscri	ot Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses t	o characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrer	t chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospecti	ve longitudinal biomarker study
Manuscri	ot number (if known):TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	
	nase summarize the above connone.		

Date: Ap	ril. 29 th , 2022
Your Name:	Frederick Klauschen
Manuscript 1	itle: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to c	haracterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent c	hemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective I	ongitudinal biomarker study
Manuscript r	number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XYes	BMS, Merck, Agilent, Novartis, Roche, Lilly, MSD
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
Ŭ	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X Yes	Dr. Klauschen is co-founder of the company `Aignostics
	financial interests		GmbH'

Dr. Klauschen is co-founder of the company `Aignostics GmbH' and receives honoraria from BMS, Merck, Agilent, Novartis, Roche, Lilly, MSD

Please place an "X" next to the following statement to indicate your agreement:

Date:	_02.12.2021
Your Nan	Jörg Kumbrink
Manuscri	itle: Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses
	tumor response and control in patients with unresectable stage III NSCLC treated with concurrent
chemora	herapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a prospective
longitudi	biomarker study
Manuscri	number (if known):
In the inte	st of transparency, we ask you to disclose all relationships/activities/interests listed below that are

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All		planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Roche Pharma	Payment or honoraria for lectures, presentations, speakers bureau
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	AstraZeneca Novartis	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	AstraZeneca	Participation on an Advisory Board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

J.K. received honoraria and reimbursement for travel and accommodation from AstraZeneca, Novartis, and Roche Pharma.

Please place an "X" next to the following statement to indicate your agreement:
_x I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 3. 12. 21	
Your Name: Jeus Neumann	Pierre la sell malanda parale man has
Manuscript Title: Prospective evaluation of	l'immedogical moleculasquebe, image basan
Manuscript number (if known):	(PRECISION)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None None	t 30 months
3	Royalties or licenses	None	
4	Consulting fees	None	

	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	Honorana for Occhres and presentations	BMS and Pher	
	manuscript writing or educational events	achoes and presentations	BMS and Phro	
		None		
	testimony			
	Support for attending meetings and/or travel	None		
	Patents planned, issued or pending	<u>X</u> None		
	Participation on a Data Safety Monitoring Board or	None		
	Advisory Board Leadership or fiduciary role	None		
	in other board, society, committee or advocacy	None		
	group, paid or unpaid Stock or stock options	None		
)	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None		
3	services Other financial or non-			
	financial interests			
Ple	ease summarize the above o	conflict of interest in the foll	owing box:	7
L	A CONTRACTOR OF THE CONTRACTOR			
Ple	ease place an "X" next to th	ne following statement to inc	dicate your agreement:	
				s on
\geq	I certify that I have answ form.	ered every question and have	ve not altered the wording of any of the questions	

Date: Apri	il. 29 th , 2022
Your Name: _	Alexander Nieto
Manuscript Ti	tle: Prospective evaluation of immunological, molecular-genetic, image-based and microbial
analyses to ch	aracterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent ch	emoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective lo	ongitudinal biomarker study
Manuscript nu	umber (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	S ,		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
-5	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None.		
Ple	ease place an "X" next to the	following statement to in	dicate your agreement:

Date: <u>April. 29th, 2022</u>	
Your Name: Elfriede Noessner	
Manuscript Title: Prospective	ve evaluation of immunological, molecular-genetic, image-based and microbial
analyses to characterize tumor resp	onse and control in patients with unresectable stage III NSCLC treated with
concurrent chemoradiotherapy foll	owed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudinal biomarker	study
Manuscript number (if known):	TLCR-21-1010-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XYes	Phio Pharmaceuticals (Inst)
3	Royalties or licenses	XYes	Medigne (Inst)

4	Consulting fees	XNone	
5	Payment or honoraria for	XYes	Astrazeneca, Hexal, Ipsen, Roche
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XYes	Definiens, Visiopharm
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
	ilitaticiai iliterests		

Dr. Noessner receives honoraria from Astrazeneca, Hexal, Ipsen and Roche. Dr. Noessner serves in consulting or advisory board of Definiens and Visiopharm. Dr. Noessner receives research funding from Phio Pharmaceuticals (Inst). Dr. Noessner receives royalties or licenses from Medigne (Inst).

Please place an "X" next to the following statement to indicate your agreement:

Date	e: <u>April 25th, 2022</u>						
You	Your Name: Carolyn Judith Pelikan						
Mar	Manuscript Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbial						
<u>ana</u>	analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with						
con	current chemoraditherapy for	ollowed by consolidation t	herapy with durvalumab (PRECISION): protocol for a				
pros	spective longitudinal biomar	rker study					
Mar	nuscript number (if known):						
		<u>-</u>	elationships/activities/interests listed below that are				
		· · · · · · · · · · · · · · · · · · ·	ns any relation with for-profit or not-for-profit third				
•		-	the manuscript. Disclosure represents a commitment				
		-	f you are in doubt about whether to list a				
rela	tionship/activity/interest, it	is preferable that you do s	50.				
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the current				
to tl	ne epidemiology of hypertentication, even if that medica	nsion, you should declare a tion is not mentioned in th	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. in this manuscript without time limit. For all other items,				
	time frame for disclosure is	•	, , , , , , , , , , , , , , , , , , ,				
		•					
		Name all entities with	Specifications/Comments				
		whom you have this	(e.g., if payments were made to you or to your				
		relationship or indicate none (add rows as	institution)				
		needed)					
		Time frame: Since the initial	planning of the work				
1	All support for the present	XNone					
	manuscript (e.g., funding, provision of study materials,						
	medical writing, article						
	processing charges, etc.)						
	No time limit for this item.						
		Time frame: past	36 months				
2	Grants or contracts from	XNone					

any entity (if not indicated

X_None

in item #1 above).

Royalties or licenses

4	Consulting fees	XNone	
_			
5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the foll	owing box:
N	lone.		
Dlaa	se place an "X" next to the	following statement to inc	icate vour agreement:
1100	ise place all A liext to tile	ionowing statement to inc	icate your agreement.

Date: April. 29 th , 2022
Your Name: Niels Reinmuth
Manuscript Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbi
analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudinal biomarker study
Manuscript number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XYes	AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, and Takeda
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	XYes	AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, and Takeda.
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Dr. Reinmuth reports receiving honoraria for speaker activities and participation in advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, and Takeda.

Please place an "X" next to the following statement to indicate your agreement:

Date:	- Dec loly			
Your Name:	Schula.	Chista		
Manuscript Title:_	Propective	evaluation	1 innualor	col, molecular.
Manuscript numb	er (if known):		4	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Jump cetus Jump	
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	_X_None	

5	Payment or honoraria for	None
	lectures, presentations,	70-222 - 6-100
	speakers bureaus,	
	manuscript writing or	Fell tow-ser
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending	<u>X</u> _None
	meetings and/or travel	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	sciente & creta, to new 201-co-x->
	committee or advocacy	U - u - pard
4.4	group, paid or unpaid	
11	Stock or stock options	None
12	Descipt of accions and	√ N
17	Receipt of equipment, materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	7

3027 C	this of	heter	4-0	-643 (L)	Min	et line:	ezt
					×		

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Klinikum der Universität München-Großhadern PV Dr. Christian Schulz Medizinische Klinik Marchioninistraße 15, 81377 München Tel. 089 4400-72391, Fax 089 4400-78887

Date:	April. 29 th , 2022
Your Nam	ne: Amanda Tufman
Manuscrij	pt Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses t	to characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrer	nt chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospectiv	ve longitudinal biomarker study
Manuscrij	pt number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XYes	AstraZeneca und Takeda.
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations,	XYes	Lilly, Pfizer, MSD, BMS, GSK, Celgene, Roche, Takeda, Boehringer Ingelheim, Amgen, AstraZeneca
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XYes	Pfizer, Amgen
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data Safety Monitoring Board or	XYes	Lilly, Pfizer, MSD, BMS, GSK, Celgene, Roche, Takeda, Boehringer Ingelheim, Amgen, AstraZeneca
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		

AT serves in the advisory boards: Lilly, Pfizer, MSD, BMS, GSK, Celgene, Roche, Takeda, Boehringer Ingelheim, Amgen, AstraZeneca. Projects financed by AstraZeneca und Takeda. AT receives support for attending meetings and/or travel from Pfizer and Amgen.

Please place an "X" next to the following statement to indicate your agreement:

form.

Date: Ap	oril. 29 th , 2022
Your Name:	Marcus Unterrainer
Manuscript ¹	Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to	characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent o	chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective	longitudinal biomarker study
Manuscript	number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid X_None X_None X_None X_None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services	5	Payment or honoraria for	X None	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
educational events 6				
Fayment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None				
testimony Support for attending meetings and/or travel Barrian Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Expone Patents planned, issued orX_None	6		X None	
meetings and/or travel		·		
meetings and/or travel	_			
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services X None	7		XNone	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X_None X_None Receipt of equipment, materials, drugs, medical writing, gifts or other services X_None		, , , , , , , , , , , , , , , , , , ,		
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X_None X_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X_None X_None Receipt of equipment, materials, drugs, medical writing, gifts or other services X_None	8	Patents planned, issued or	X None	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 2 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 2 Receipt of equipment, materials, drugs, medical writing, gifts or other services				
Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Advisory Board X_None X_None X_None X_None	9		XNone	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Lambda				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services X_None	10	•	X None	
group, paid or unpaid Stock or stock options X_None Receipt of equipment, materials, drugs, medical writing, gifts or other services X_None		in other board, society,		
11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services X_None				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services	11		V None	
materials, drugs, medical writing, gifts or other services	11	Stock of Stock options	xnone	
materials, drugs, medical writing, gifts or other services				
writing, gifts or other services	12	materials, drugs, medical	X_None	
services				
TO Other interior of from	13		X None	
financial interests	13		XNone	
Please summarize the above conflict of interest in the following box:	Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
None		None		
Please place an "X" next to the following statement to indicate your agreement:	_ _		. fallanda a akota o a ata	dianta managaran and

Date:	April. 29 th , 2022
Your Nam	ne: Peter Bartenstein
Manuscri	pt Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbi
analyses t	to characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrer	nt chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospecti	ve longitudinal biomarker study
Manuscri	pt number (if known): <u>TLCR-21-1010</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
0	pending	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	X_ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
٠.			

None			
None			

Please place an "X" next to the following statement to indicate your agreement:

X_ I certify that I have answered form.	d every question and h	ave not altered the v	vording of any of the	questions on this
		4		

Date:	April. 29 th , 2022
Your Name	e: Benedikt Flörsch
Manuscrip	t Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to	o characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent	t chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospectiv	e longitudinal biomarker study
Manuscrip	ot number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	X None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	S ,		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
-5	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	llowing box:
	None.		
Ple	ease place an "X" next to the	following statement to in	dicate your agreement:

Date: April. 29 th , 2022
Your Name: Thomas Hofer
Manuscript Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudinal biomarker study
Manuscript number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
0	pending	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	•		
12	Receipt of equipment,	X_ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
٠.			

None			
None			

Please place an "X" next to the following statement to indicate your agreement:

Date: April. 29 th , 2022
Your Name: Andreas Jung
Manuscript Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudinal biomarker study
Manuscript number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XYes	Amgen, Astra Zeneca, Bayer Pharmaceuticals, BMS,
	lectures, presentations,		Boehringer Ingelheim, Merck KGaA, Novartis, Qiagen,
	speakers bureaus, manuscript writing or		Roche Pharma and Takeda
	educational events		
6	Payment for expert	X None	
0	testimony	XNone	
	testimony		
7	Support for attending	XYes	Amgen, Astra Zeneca, Bayer Pharmaceuticals, BMS,
	meetings and/or travel		Boehringer Ingelheim, Merck KGaA, Novartis, Qiagen,
	,		Roche Pharma and Takeda
8	Patents planned, issued or	X None	
0	pending		
	pending		
_	Posticipation on a Data	V Van	Avenue Astro Zeroso Dever Discourse continuis DNAS
9	Participation on a Data Safety Monitoring Board or	XYes	Amgen, Astra Zeneca, Bayer Pharmaceuticals, BMS, Boehringer Ingelheim, Merck KGaA, Novartis, Qiagen,
	Advisory Board		Roche Pharma and Takeda
	Advisory Board		Notife i Haima and Takeda
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Dr Jung receives honoraria, worked in consulting or advisory role and received expenses for travel and accomodations by Amgen, Astra Zeneca, Bayer Pharmaceuticals, BMS, Boehringer Ingelheim, Merck KGaA, Novartis, Qiagen, Roche Pharma and Takeda.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on th form.	is

Date: Ap	oril. 29 th , 2022
Your Name:	Claus Belka
Manuscript 1	Title: Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to o	characterize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent c	chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective	longitudinal biomarker study
Manuscript i	number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XYes	Viewray, Brainlab, ELEKTA
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
_			5146 506U5 14550V 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5	Payment or honoraria for lectures, presentations,	XYes	BMS, ROCHE, MERCK, Astrazeneca, Viewray
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XYes	BMS, ROCHE, MERCK, Astrazeneca, Viewray
,	meetings and/or travel	^	bivis, Noche, Menck, Astrazeneta, Viewray
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X YES	ESTRO
	in other board, society,		251110
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
12		^_NUITE	
	services		
13	Other financial or non- financial interests	XNone	

CB receives grants or contracts from any entity but not related to this manuscript from Viewray, Brainlab and ELEKTA. CB receives honoraria from BMS, ROCHE, MERCK, Astrazeneca and Viewray. CB receives BMS, ROCHE, MERCK, Astrazeneca and Viewray. CB serves in a fiduciary role in the ESTRO.

Please place an "X" next to the following statement to indicate your agreement:

Date: April. 29 th , 2	2022
Your Name: Far	chad Manapov
Manuscript Title:	Prospective evaluation of immunological, molecular-genetic, image-based and microbia
analyses to character	ize tumor response and control in patients with unresectable stage III NSCLC treated with
concurrent chemorad	liotherapy followed by consolidation therapy with durvalumab (PRECISION): protocol for a
prospective longitudi	nal biomarker study
Manuscript number (if known): TLCR-21-1010

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XYes	FM receives an unrestricted Research Institutional Grant from AstraZeneca
2	Grants or contracts from any entity (if not indicated	Time frame: pastXNone	36 months
3	in item #1 above). Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	XYes	AstraZeneca, Novartis, Roche, Lilly, Elekta, Brainlab
	educational events	V N	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XYes	BMS, ROCHE, MERCK, Astrazeneca, Viewray
	Datasta alausa di 'assa da s	V. Name	
8	Patents planned, issued or pending	XNone	
	pending		
9	Participation on a Data	X Yes	AstraZeneca, Novartis
,	Safety Monitoring Board or Advisory Board		Astrazeneca, Novartis
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

FM receives an unrestricted Research Institutional Grant from AstraZeneca. FM receives honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab. FM serves in the advisory board of AstraZeneca, Novartis.

Please place an "X" next to the following statement to indicate your agreement: